Valbenazine · Ingrezza
Small molecule
Evidence outlook
Approved: Tardive Dyskinesia, Huntington's Disease Chorea, Huntington's Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Tardive dyskinesia (DYSVAL capsules 40 mg, Mitsubishi Tanabe Pharma)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
KINECT-HD NCT04102579 · Huntington's Disease Chorea KINECT-HD was a randomized, quadruple-masked, placebo-controlled trial in 128 patients with chorea associated with Huntington's disease. Its primary endpoint, the change in the UHDRS Total Maximal Chorea score, is a validated clinical rating and was met (treatment effect -3.2 units, p<0.0001). The sources read give no power calculation, so the grade is moderate. Registry: NCT04102579 | 3 | Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score. (Baseline (average of screening and Day -1), maintenance (average of Weeks 10 and 12)) 2021-10-15 | Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Huntington's Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Valbenazine (Ingrezza): this drug | Approved | Small molecule | vesicular monoamine transporter 2 (VMAT2) | Partial signal | NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD). | |
| Votoplam | Phase 3 | Small molecule | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tanruprubart | Phase 2 | Monoclonal antibody | Complement C1q | not yet graded | No reviewed efficacy summary in this indication | |
| Ifezuntirgene Inilparvovec | Phase 1/2 | Gene therapy / editing | Huntingtin (HTT) gene | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-003 | Phase 1/2 | RNA / oligonucleotide | Huntingtin (HTT) | Weak signal | NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results). | |
| Brezosiran | Phase 1 | RNA / oligonucleotide | Huntingtin (HTT) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6662 | —(overall) | Gene therapy / editing | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ingrezza (Valbenazine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent